Overall rank by patents
#34,698
of 49,997 tracked assignees
USPTO PatentsView assignee record - 7 granted patents across 9 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G06T (Image Data Processing OR Generation, IN General).
The verdict
According to USPTO PatentsView, Cellavision ranks #34,698 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 9 technology areas.
USPTO PatentsView assignee plate
Corpus R34698 · Foreign Corporation #34,698 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
Nearest grant-volume peer: Catheter Connections, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
CellaVision AB · this assignee
34 score
3D Lighting… · lowest
7 score
What this shows Cellavision's Innovation Score is 33.7/100 (45th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
CellaVision AB is a focused PatentsView assignee: 9 CPC subclasses with 57.1% of grants classified under G06T (Image Data Processing OR Generation, IN General). Peak complete grant year is 2017 (3 grants) versus a trough of 1 in 2015. By volume, Cellavision sits between Catheter Connections, Inc. and Cellotape, Inc..
CellaVision AB shows 1 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Catheter Connections, Inc.
7 patents
Cazena, Inc.
7 patents
Cegnum LLC
7 patents
Cell and Molecular Tissue Engineering, LLC
7 patents
Cellaed Life Saver PTY Ltd
7 patents
Cellink AB
7 patents
Cellink Bioprinting AB
7 patents
Cellotape, Inc.
7 patents
CellaVision AB
7 patents
What this shows CellaVision holds 7 patents at rank #34,802, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #34,802 in granted patent volume.
Other assignees with the most granted patents in CellaVision's primary technology class.
Cellavision's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
34 45th percentile higher than 45% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 14.3% |
| 2017 | 3 | 42.9% |
| 2018 | 1 | 14.3% |
| 2019 | 1 | 14.3% |
| 2024 | 1 | 14.3% |
Top 9 of 9 technology areas
Overall rank by patents
#34,698
of 49,997 tracked assignees
33.7 out of 100
What to do with this data
CellaVision AB's patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.